The Tumor Lysis Syndrome
By Scott C. Howard, Deborah P. Jones, Ching-Hon Pui. New England Journal of Medicine, 2011
1,021 citations recorded by the source corpus.
The tumor lysis syndrome is the most common disease-related emergency in children and adults with hematologic cancers. This review summarizes current strategies for risk assessment, prophylaxis, and therapy.
Subfields: Oncology, Pediatrics, Perinatology and Child Health, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/281c7f56a8467517546ad3dfbd094fb060eff6f8
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- Joshua Charles Denny
- Mia A. Levy
- Thomas A. Lasko
- A. Shimabukuro-Vornhagen
- M. V. von Bergwelt-Baildon
- M. Subklewe
- Philipp Gödel
- H. Schlößer
Citations in the corpus
- Cytokine release syndrome (2018, background): “Although tumor lysis syndrome usually can be readily discriminated from CRS on the basis of characteristic laboratory abnormalities such as hyperuricemia, hyperkalemia, hyperphosphatemia and hypocalcemia, it can sometimes be difficult to determine if CRS and tumor lysis syndrome occur concurrently [”
- Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. (2017, neutral): “Vomiting 23 (22) 5 (23) 6 (18) 12 (24) 0 0 0 0 Constipation 22 (21) 6 (27) 7 (21) 9 (18) 2 (2) 1 (5) 1 (3) 0 Headache 19 (18) 2 (9) 7 (21) 10 (20) 0 0 0 0 Anemia 18 (17) 7 (32) 6 (18) 5 (10) 16 (15) 7 (32) 5 (15) 4 (8) Cough 18 (17) 7 (32) 6 (18) 5 (10) 1 (1) 1 (5) 0 0 Neutropenia 18 (17) 4 (18) 8 (”
- Computational Phenotype Discovery Using Unsupervised Feature Learning over Noisy, Sparse, and Irregular Clinical Data (2013, background): “In some neoplastic diseases such as acute leukemias, continuous white blood cell turnover raises uric acid concentration throughout the course of the disease, and tumor lysis syndrome [37] can occur with the bolus of purines released from cells after a chemotherapy treatment.”
- Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia (2015, neutral): “Chromosome 17p deletion 19/49 (39) 12/53 (23) 31/102 (30)”